[1] |
HE Xueru, FU Yuhao, XUN Xuejiao, CUI Yanjun, DONG Zhanjun.
Advances in uridine diphosphate glucuronosyltransferase-mediated drug interactions with tyrosine kinase inhibitors
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(8): 936-945.
|
[2] |
LIU Lu, CHEN Xiaoyan.
Current status of clinical drug-drug interactions research of innovative small molecule drugs in China
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(8): 863-875.
|
[3] |
MENG Qiang, LIU Kexin.
Research status and prospect of transporter-mediated drug-drug interactions
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(8): 876-888.
|
[4] |
SUN Bo, FU Shujun, CHEN Guiliang, LI Li.
Applications of Drug Interaction Study in New Drug Development and Regulartory Decision-making
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(10): 1095-1102.
|
[5] |
WU Qiaoyu, YUAN Hong, LU Yao.
Evaluation of the effects of resveratrol on the activity human cytochrome P450 through combined probe method
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(4): 426-432.
|
[6] |
SHA Bijun, ZHOU Sufeng, WANG Lu, ZHAO Yuqing, CHEN Xijing, SHAO Feng.
Methods and progress of clinical research on drug-drug interactions
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(9): 1037-1045.
|
[7] |
WEN Chunjie, ZHANG Ying, WU Lanxiang, ZHOU Honghao.
Inhibitory effect of vemurafenib on UGT1A1-mediated irinotecan metabolism
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(7): 773-777.
|
[8] |
SHAN Xiaolei, FU Shujun, GAO Guanghua, SUN Tao, WANG Qingli, YU Shanshan.
Metabolism- and transporter-mediated drug-drug interaction-overview of in vitro study and cases analysis
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(10): 1165-1171.
|
[9] |
LI Li, YANG Jinbo.
Strategies of clinical drug-drug interaction studies and application progress of physiologically-based pharmacokinetic model
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(10): 1085-1091.
|
[10] |
LI Xiao-nan, CHEN Jia-yin, SUN Xiao-lin, ZHANG Yong-jie, WANG Chun-feng, WEN Yan-li, WANG Sui-loU, CHEN Xi-jing.
Research progress of organic cation transporters
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2013, 18(8): 954-960.
|
[11] |
LI Dan, HAN Yong-long, YU Tao, Fu Yao, MENG Xiang-le, YU Qi, GUO Cheng.
In vitro inhibition of Huanglianjiedu Decoction on 6 cytochrome P450 isoforms in human liver microsomes
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2012, 17(2): 131-136.
|
[12] |
ZHU Jian-ping, SUN Jian-guo, PENG Ying, WANG Guang-ji.
Prediction of key pharmacokinetic parameters in human
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2011, 16(6): 699-709.
|
[13] |
GUO Jian-jun, ZHAO Hua, WANG Jing-jing.
In vitro prediction of CYP-mediated inhibitory drug and drug interaction
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2009, 14(8): 841-848.
|
[14] |
LI Xiao-yu, LIU Gao-lin, ZHOU Jia-chun, QIAN Gang, GAO Jun-wei, SUN Bo, GUO Yan-kun.
Experimental study on the effects of liver cytochrome protein 450 (CYP450) induced by panax notoginsenoside injection in rats
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2009, 14(8): 849-854.
|
[15] |
HAN Yong-long, YU Qi, MENG Xiang-le, LI Dan, BIAN Ka, GUO Cheng.
Inhibition of Dengzhanxixin injection on rat liver microsomal CYP3A
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2009, 14(8): 891-895.
|